Latest stories on CNTX
Context Therapeutics doses first patient in CT-202 trial
The Fly63 · neutralproduct/pr
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
GlobeNewswire63 · neutralproduct/pr
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Business Insider63 · neutralproduct/pr
Intersignal Demonstrates Cross-Network Context Continuity Between Local AI Models
PR Newswire56 · neutralproduct/pr
Context downgraded to Market Perform from Outperform at LifeSci Capital
The Fly48 · neutralanalyst
Context Therapeutics Price Target Lowered To 3 From 4 At Citizens
The Fly34 · bearishanalyst
Context Therapeutics GAAP EPS of -$0.15
Seeking Alpha34 · bearishearnings
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
TipRanks56 · neutralproduct/pr
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K50 · neutralgeneral
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
StockTitan56 · neutralproduct/pr
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K34 · bearishgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CNTX Stock News
StockTitan50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart50 · neutralgeneral
WitnessAI Unveils NER-D, a Breakthrough AI Model for Context-Aware Sensitive-Data Detection
PR Newswire63 · neutralproduct/pr
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | CNTX Stock News
StockTitan63 · neutralgeneral
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish
Yahoo Top58 · neutralanalyst
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K50 · neutralgeneral
Convr® Makes the Industry's Only Commercial P&C Risk Context Engine Available to AI Agents via Model Context Protocol (MCP)
PR Newswire63 · neutralproduct/pr
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip
Stocktwits News42 · neutralearnings
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
TipRanks67 · bullishproduct/pr
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CNTX Stock News
StockTitan50 · neutralgeneral